■ 学会名
16th Asian Conference on Pharmacoepidemiology and 29th Japanese Conference on Pharmacoepidemiology joint meeting

■ 発表日
2024/10/13

■ 筆頭演者
Kazuhiko Takahata¹
1) Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan

■ 共同演者
Shingo Akutsu¹, Eiichi Tanaka², Ryoko Sakai¹,², Manabu Akazawa¹
1) Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan
2) Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

■ 発表形態
Poster

■ 要旨
Aims:To evaluate the impact of self-injection (SI) on medical cost in patients with rheumatoid arthritis (RA) between patients who have selected SI and those who had not in the public healthcare payer’s perspective.

Methods:We conducted a retrospective cohort study using claims data from April 2014 to August 2023, which was provided from DeSC Healthcare, Inc. We defined patients with RA by both disease code and bDMARDs prescription and classified patients who have selected SI (SI group) and those who had not (non-SI group). Patients’characteristics were used to calculate a propensity score. One-to-one matching was performed, and we calculated the average of total direct health care cost from the public healthcare payer’s perspective in $/patient/month in each group.

Results:Total of 6,844 patients (mean age:73.5 years, female:73.0%) were matched and the total direct health care cost were 1,217 ($/patient/month) in the SI group,and 970 ($/patient/month) in the non-SI group, respectively (I USD = 140 JPY in 2024).

Conclusion: Total direct health care cost was higher in the SI group compared to the non-SI group.